PURE (PURE Bioscience) Cyclically Adjusted Revenue per Share: $0.04 (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PURE Bioscience Cyclically Adjusted Revenue per Share?

PURE Bioscience PURE +13.17% Cyclically Adjusted Revenue per Share is $0.04 as of Apr. 2026. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

PURE Bioscience's adjusted revenue per share for the three months ended in Apr. 2026 was $0.005. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.04 for the trailing ten years ended in Apr. 2026.

During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -8.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -15.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of PURE Bioscience was 38.70% per year. The lowest was -60.70% per year. And the median was -17.90% per year.

As of today (2026-07-25), PURE Bioscience's current stock price is $0.07673. PURE Bioscience's Cyclically Adjusted Revenue per Share for the quarter that ended in Apr. 2026 was $0.04. PURE Bioscience's Cyclically Adjusted PS Ratio of today is 1.92.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PURE Bioscience was 32.00. The lowest was 0.98. And the median was 4.48.


PURE Bioscience  (OTCPK:PURE) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

PURE Bioscience's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.07673/0.04
=1.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PURE Bioscience was 32.00. The lowest was 0.98. And the median was 4.48.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


PURE Bioscience Cyclically Adjusted Revenue per Share Related Terms


PURE Bioscience Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for PURE Bioscience's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PURE Bioscience Cyclically Adjusted Revenue per Share Chart

PURE Bioscience Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.04 0.04 0.04 0.04

PURE Bioscience Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.04 0.04 0.04

PURE vs DQWS, RAY, TANH: Cyclically Adjusted Revenue per Share Comparison

For the Household & Personal Products subindustry, PURE Bioscience's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PURE Bioscience Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, PURE Bioscience's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PURE Bioscience's Cyclically Adjusted PS Ratio falls into.



PURE Bioscience Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PURE Bioscience's adjusted Revenue per Share data for the three months ended in Apr. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=0.005/333.0200*333.0200
=0.005

Current CPI (Apr. 2026) = 333.0200.

PURE Bioscience Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201607 0.008 240.628 0.011
201610 0.008 241.729 0.011
201701 0.007 242.839 0.010
201704 0.005 244.524 0.007
201707 0.008 244.786 0.011
201710 0.007 246.663 0.009
201801 0.006 247.867 0.008
201804 0.006 250.546 0.008
201807 0.007 252.006 0.009
201810 0.008 252.885 0.011
201901 0.006 251.712 0.008
201904 0.004 255.548 0.005
201907 0.008 256.571 0.010
201910 0.005 257.346 0.006
202001 0.004 257.971 0.005
202004 0.026 256.389 0.034
202007 0.041 259.101 0.053
202010 0.018 260.388 0.023
202101 0.011 261.582 0.014
202104 0.006 267.054 0.007
202107 0.010 273.003 0.012
202110 0.006 276.589 0.007
202201 0.005 281.148 0.006
202204 0.006 289.109 0.007
202207 0.004 296.276 0.004
202210 0.004 298.012 0.004
202301 0.004 299.170 0.004
202304 0.004 303.363 0.004
202307 0.005 305.691 0.005
202310 0.006 307.671 0.006
202401 0.003 308.417 0.003
202404 0.004 313.548 0.004
202407 0.004 314.540 0.004
202410 0.005 315.664 0.005
202501 0.003 317.671 0.003
202504 0.004 320.795 0.004
202507 0.007 323.048 0.007
202510 0.006 0.000
202601 0.004 325.252 0.004
202604 0.005 333.020 0.005

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.04 mean?
PURE Bioscience (PURE) has a Cyclically Adjusted Revenue per Share of $0.04 as of Apr. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PURE Bioscience and its competitors.
Is PURE Bioscience's Cyclically Adjusted Revenue per Share too high?
PURE Bioscience's current Cyclically Adjusted Revenue per Share is $0.04.
How does PURE Bioscience's Cyclically Adjusted Revenue per Share compare to DQWS and RAY?
PURE Bioscience's Cyclically Adjusted Revenue per Share of $0.04 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PURE Bioscience and its competitors. PURE Bioscience's current Cyclically Adjusted Revenue per Share is $0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PURE Bioscience stock overvalued right now?
Based on GuruFocus' analysis, PURE Bioscience (PURE) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.10, compared to a current price of $0.08 — trading 23.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For PURE Bioscience (PURE), the current Cyclically Adjusted Revenue per Share is $0.04 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PURE Bioscience Business Description

Address 771 Jamacha Road, No. 512, El Cajon, CA, USA, 92019
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, and products preserved with SDC and SDC as a raw material ingredient for manufacturing use. The company generates revenue from the sale of its antimicrobial products.